Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Visual performance and initial perceptions of a wearable Electronic Vision Enhancement System by people with age-related macular degeneration.
Author Affiliations & Notes
  • Andrew Miller
    Vision and Hearing Sciences Research Centre, Anglia Ruskin University, Cambridge, United Kingdom
  • Michael D. Crossland
    Institute of Ophthalmology, University College London, London, United Kingdom
    NIHR Moorfields Biomedical Research Centre, London, Greater London, United Kingdom
  • Jane Macnaughton
    Vision and Hearing Sciences Research Centre, Anglia Ruskin University, Cambridge, United Kingdom
  • Keziah Latham
    Vision and Hearing Sciences Research Centre, Anglia Ruskin University, Cambridge, United Kingdom
  • Footnotes
    Commercial Relationships   Andrew Miller None; Michael Crossland Oxsight , Code S (non-remunerative); Jane Macnaughton None; Keziah Latham None
  • Footnotes
    Support  Macular Society (UK) PhD scholarship to Andrew Miller
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5428. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrew Miller, Michael D. Crossland, Jane Macnaughton, Keziah Latham; Visual performance and initial perceptions of a wearable Electronic Vision Enhancement System by people with age-related macular degeneration.. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5428.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : As part of a larger study to understand the usefulness of an Augmented Reality (AR) style wearable Electronic Vision Enhancement System (wEVES) for people with age-related macular degeneration (AMD) a baseline assessment was conducted to evaluate visual function and initial qualitative views.

Methods : 30 people (60% female, mean age 81±7yrs) with AMD had a low vision assessment to optimise optical low vision aids (LVAs). Participants were familiarised with the Eye5 device (Eyedaptic, Los Angeles), which includes a wearable display and a selectable head-mounted (HM) or handheld (HH) camera input system. Distance Visual Acuity (VA), reading acuity and contrast sensitivity (CS) with the device were compared to measures taken with best-corrected spectacles and LVAs. Participants’ initial perceptions of the device were invited, along with their willingness to participate in a longer home trial.

Results : Repeated measures ANOVA showed significant changes with the device compared to spectacles in distance VA (F(1.29, 37.46)=44.03, p<0.001) and reading acuity (F(1.98, 57.36)=24.45, p<0.001), but not CS (F(1.63, 47.20)=1.44, p=0.246).
Post hoc analysis showed improvements in distance VA compared to spectacles with both the HH camera (0.41logMAR [95% CI, 0.27 to 0.55], p<0.001) and HM (0.36logMAR [95% CI, 0.22 to 0.49], p<0.001). Compared to spectacles, reading acuity improved with the HH camera (20.6points [95% CI,11.1 to 30.1], p<0.001), but not with the HM camera (10.0points [95% CI, 20.2 to -0.2], p=0.055). Compared to the optimal optical LVA, reading acuity was similar with the HH camera (-1.54points [95% CI, -5.4 to 2.3] p=1.0) and poorer with the HM camera (-12.1points [95% CI, -4.0 to -20.2], p=0.01).
27/30 participants (90%) were willing to take part in a home trial to evaluate real-world use of the device, with 3 abandoning due to lack of improvement (3), comfort (1), and diplopia (2). 10/30 felt the device offered more flexibility than current LVAs and 6 described hands-free use as beneficial. Main disadvantages reported were screen quality or size (6), poor tactile controls (6) and the wire connecting headset and phone (5).

Conclusions : This AR style wEVES showed improvement in VA but not in contrast sensitivity. Most participants saw advantages to the device and there was a strong willingness by participants to take part in a home trial.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×